top of page
PROMISE
phe885
DREAMM 5
PROMISE
1/50
RRMM
2022 - (R) NCT05308654
Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
2021 - (R) NCT05121103
Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
2021 - (R) NCT04771078
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial R
2021 - (R) NCT04756726
Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
2021 - (R) NCT04754100
Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma
2021 - (NYR) NCT05027594
NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
2021 - (R) NCT04975997
Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Multiple Myeloma
2020 - (R) NCT04688853
Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM
2020 - (R) NCT04674813
Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma
2020 - (R) NCT04570631
Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
2020 - (R) NCT04557098
Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
2020 - (R) NCT04505813
Phase 1- Antigen-specific T Cell Therapy NEXI 002 Relapsed Refractory Multiple Myeloma
NDMM
2021 - (R) NCT05123131
Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)
2021 - (R) NCT04923893
Phase 3 - Bort/Len/Dex f/b Cilta-cel f/b Len/Dex NDMM- ( No ASCT planned ) CARTITUDE-5
2020- (R) NCT04653246
Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
2020 (R) NCT04634435
Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM
2020 - (R) NCT04430894
Phase 2: KRDI in Transplant-Eligible MM
2019 - (R) NCT04009109
Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2018 - (R) NCT03500445
Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
2015 - (R) NCT02343042
Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
2010 - (Active) NCT01208662
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
MGUS/SMM
2021 - (R) PCROWD
The PCROWD Study invites people with precursor conditions to Share samples a few times each year
2021 - (R) NCT04850846
Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM
2021 - (R) NCT04775550
Phase 2: DARA RVD For High Risk SMM (PRISM)
2020 - (R) NCT04270409
Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
2020 - (R) IMPACT Study
IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test
2018 - (R) NCT03689595
PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population
2018 - (R) NCT03657251
MMRF CureCloud Research Initiative
2017 - (Active) NCT03236428
Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM
2016 - (R) NCT02886065
Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
bottom of page